Øyvind S. Bruland

Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer

Chris Parker, Sten Nilsson, Daniel Heinrich et al. · New England Journal of Medicine · 2013 · 3.3K citations

Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study

Sten Nilsson, Lars Franzén, Christopher Parker et al. · The Lancet Oncology · 2007 · 491 citations

Bone-targeted Radium-223, Urology, Genitourinary Cancer +6

Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial

Oliver Sartor, Robert L. Coleman, Sten Nilsson et al. · The Lancet Oncology · 2014 · 485 citations

Urology, Oncology, Medicine +8

Bone health in cancer: ESMO Clinical Practice Guidelines

Robert E. Coleman, Peyman Hadji, Jean‐Jacques Body et al. · Annals of Oncology · 2020 · 481 citations · Full text

First Clinical Experience with α-Emitting Radium-223 in the Treatment of Skeletal Metastases

Sten Nilsson, Roy H. Larsen, Sophie D. Fosså et al. · Clinical Cancer Research · 2005 · 430 citations